Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) Increases Despite Market Slip: Here's What You Need to Know
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $31.86, signifying a +1.01% move from its prior day's close.
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
I anticipate the FDA will soon declare the semaglutide shortage resolved, potentially slowing Hims' revenue growth rate due to compounding restrictions. I foresee explosive revenue growth post-FDA announcement due to 60-day timelines for pharmacies (503A) and 90-day timelines for outsourcing facilities (503B) to comply with the restrictions. I believe HIMS may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings, creating uncertainty for speculators betting against the stock.
Is Hims & Hers Health Stock a Buy?
Established in 2017, Hims & Hers Health (HIMS -1.17%) is a relatively young company addressing age-old healthcare challenges by offering prescription medications, over-the-counter products, and personal care solutions through a convenient direct-to-consumer model. Since going public via a special purpose acquisition company (SPAC) merger in 2021, the telehealth company and its stock have experienced dramatic transformations.
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $29.72, signifying a -0.3% move from its prior day's close.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: Ready To Outperform Further
Hims & Hers Health is a rapidly growing telehealth leader with a unique, customer-focused business model, demonstrated by its aggressive customer base expansion and accelerating revenue growth momentum. The company's strong operating leverage, consistent EBITDA margin expansion, and robust free cash flow have built a fortress balance sheet, enabling both organic and inorganic growth opportunities. My intrinsic value per share estimate is significantly higher compared to the current share price.
Hims & Hers Health: A Stock to Trade or Own?
Hims & Hers Health Inc. NYSE: HIMS, a telehealth company with a $6.1 billion valuation, has been a remarkable growth story, especially over the past year. The stock climbed an astounding 215% in 2024, significantly outperforming the broader market and its sector.
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for treating diabetes and losing weight. As of 11 a.m.
Is Hims & Hers Stock in Trouble?
Hims & Hers Health (HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth company has been growing at a fast rate, making it one of the best stocks to own in healthcare of late.
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $25.90, moving +1.93% from the previous trading session.
Hims & Hers Stock Is Poised for a Major Surge in 2025
Hims & Hers (HIMS -4.02%) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the stock. But the business is about much more than just one product, and Travis Hoium explains why investors should expect an expanded platform in 2025.
Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns
Hims & Hers capitalizes on telehealth growth in hair, mental, sexual health, and weight loss. Yet, limited product differentiation, reliance on branding, and FDA risks weaken its long-term moat. Forecasting $3.79B in revenue and $1.08 EPS by 2030, a $45.90 midpoint price target implies an 11.5% five-year CAGR, underperforming a 15% return expectation for a Buy rating. Despite strong branding and subscription revenue, slim competitive advantages and valuation concerns justify a Hold rating, emphasizing risks from generic pricing and market competition.
